Download Chapter 16 Cholinesterase Inhibitors

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Neuropharmacology wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Stimulant wikipedia , lookup

Psychopharmacology wikipedia , lookup

Transcript
Chapter 72
Glucocorticoids in Nonendocrine
Disorders
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Glucocorticoid Drugs


Also known as corticosteroids and nearly
identical to steroids produced by the adrenal
cortex
Physiologic effects (low doses)


Modulation of glucose metabolism in
adrenocortical insufficiency
Pharmacologic effects (high doses)

Suppression of inflammation
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
2
Glucocorticoids in
Nonendocrine Disorders

Glucocorticoid physiology





Metabolic effects
Cardiovascular effects
Effects during stress
Effects on water and electrolytes
Respiratory system in neonates
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
3
Pharmacology of Glucocorticoids

Molecular mechanisms of action different
from those of other drugs


Glucocorticoid receptors are inside the cell
Glucocorticoids modulate the production of
regulatory proteins vs. signaling pathways
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
4
Pharmacology of Glucocorticoids



Effects on metabolism and electrolytes
Anti-inflammatory and immunosuppressant
effects
Therapeutic uses in nonendocrine disorders




Rheumatoid arthritis
Systemic lupus erythematosus
Inflammatory bowel disease
Miscellaneous inflammatory disorders
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
5
Pharmacology of Glucocorticoids

Therapeutic uses in nonendocrine disorders
(cont’d)






Allergic conditions
Asthma
Dermatologic disorders
Neoplasms
Suppression of allograft rejection
Prevention of respiratory distress syndrome
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
6
Fig. 72–1. Feedback regulation of glucocorticoid synthesis and secretion.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
7
Pharmacology of Glucocorticoids

Adverse effects








Adrenal insufficiency
Osteoporosis and resultant fractures
Infection
Glucose intolerance
Myopathy
Fluid and electrolyte disturbances
Growth retardation
Psychologic disturbances
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
8
Pharmacology of Glucocorticoids

Adverse effects (cont’d)





Cataracts and glaucoma
Peptic ulcer disease
Iatrogenic Cushing’s syndrome
Use in pregnancy and lactation
Drug interactions




Interactions related to potassium loss
Nonsteroidal anti-inflammatory drugs
Insulin and oral hypoglycemics
Vaccines
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
9
Pharmacology of Glucocorticoids

Contraindications



Patients with systemic fungal infections
Those receiving live virus vaccines
Use with caution in pediatric patients and in
pregnancy/breast-feeding
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
10
Pharmacology of Glucocorticoids

Adrenal suppression



Why it can develop
Adrenal suppression and physiologic stress
Glucocorticoid withdrawal
• Taper the dosage over 7 days
• Switch from multiple doses to single doses
• Taper the dosage to 50% of physiologic values
• Monitor for signs of insufficiency
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
11
Glucocorticoid Routes
of Administration


Oral, parenteral (IV, IM, subQ), and topical
Individual glucocorticoids differ in three ways:



Biologic half-life
Mineralocorticoid potency
Glucocorticoid potency
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
12
Glucocorticoid Dosage


Highly individualized
Determined empirically (trial and error)







No immediate threat—start low and slow
Immediate threat—start high; decrease as possible
Long-time use—smallest effective amount
Prolonged treatment with high doses only if disorder
is life-threatening or has potential to cause
permanent disability
Increased in times of stress
Gradual weaning
Alternate-day therapy
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
13